{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:45:47Z","timestamp":1790045147979,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.nmd.2023.11.013","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T18:49:36Z","timestamp":1701542976000},"page":"61-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5435-4774","authenticated-orcid":false,"given":"Tamara","family":"Dangouloff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Thokala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Deconinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8le","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Daron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Delstanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Hiligsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2023.11.013_bib0001","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2023.11.013_bib0002","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D'Amico","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2023.11.013_bib0003","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.nmd.2023.11.013_bib0004","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.11.013_bib0005","doi-asserted-by":"crossref","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","article-title":"Population-based analysis of survival in spinal muscular atrophy","volume":"94","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.11.013_bib0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.11.013_bib0007","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ejpn.2019.03.004","article-title":"Quality of life of patients with spinal muscular atrophy: a systematic review","volume":"23","author":"Landfeldt","year":"2019","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.nmd.2023.11.013_bib0008","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","article-title":"Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments","volume":"16","author":"Dangouloff","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2023.11.013_bib0009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","article-title":"New treatments in spinal muscular atrophy: an overview of currently available data","volume":"21","author":"Ramdas","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nmd.2023.11.013_bib0010","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/14737175.2023.2252179","article-title":"Newborn screening for spinal muscular atrophy - what have we learned?","volume":"23","author":"De Siqueira Carvalho","year":"2023","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.nmd.2023.11.013_bib0011","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.nmd.2023.11.013_bib0012","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nmd.2019.11.002","article-title":"244th ENMC international workshop: newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands","volume":"30","author":"Dangouloff","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.11.013_bib0013","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.11.013_bib0014","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.nmd.2019.02.003","article-title":"Newborn screening for SMA in Southern Belgium","volume":"29","author":"Boemer","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.11.013_bib0015","doi-asserted-by":"crossref","first-page":"19922","DOI":"10.1038\/s41598-021-99496-2","article-title":"Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium","volume":"11","author":"Boemer","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmd.2023.11.013_bib0016","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/jnnp-2021-326344","article-title":"Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis","volume":"92","author":"Shih","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2023.11.013_bib0017","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jval.2020.04.010","article-title":"Cost-effectiveness analysis of newborn screening and treatment for spinal muscular atrophy","volume":"23","author":"Chen","year":"2020","journal-title":"Value Heal"},{"key":"10.1016\/j.nmd.2023.11.013_bib0018","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/j.jval.2020.04.805","article-title":"Cost-effectiveness analysis of newborn screening for spinal muscular atrophy (SMA) in the United States","volume":"23","author":"Arjunji","year":"2020","journal-title":"Value Heal"},{"key":"10.1016\/j.nmd.2023.11.013_bib0019","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jval.2022.06.010","article-title":"Cost-effectiveness of newborn screening for spinal muscular atrophy in The Netherlands","volume":"25","author":"Velikanova","year":"2022","journal-title":"Value Heal J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"10.1016\/j.nmd.2023.11.013_bib0020","doi-asserted-by":"crossref","unstructured":"Weidlich D., Servais L., Kausar I., Howells R., Bischof M. Cost effectiveness of newborn screening for spinal muscular atrophy in England and Wales 2023. 10.1101\/2023.02.09.23285715.","DOI":"10.1101\/2023.02.09.23285715"},{"key":"10.1016\/j.nmd.2023.11.013_bib0021","unstructured":"ICER. Spinraza\u00ae and Zolgensma\u00ae for Spinal Muscular Atrophy: effectiveness and Value 2019. https:\/\/icer-review.org\/wp-content\/uploads\/2018\/07\/ICER_SMA_Final_Evidence_Report_052419.pdf."},{"key":"10.1016\/j.nmd.2023.11.013_bib0022","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12962-020-00234-8","article-title":"Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US","volume":"18","author":"Thokala","year":"2020","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.nmd.2023.11.013_bib0023","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13023-020-01367-y","article-title":"Natural history of lung function in spinal muscular atrophy","volume":"15","author":"Wijngaarde","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2023.11.013_bib0024","unstructured":"StatBel. Tables de mortalit\u00e9 et esp\u00e9rance de vie. Serv Public F\u00e9d\u00e9ral Belge 2021. https:\/\/statbel.fgov.be\/fr\/themes\/population\/mortalite-et-esperance-de-vie\/tables-de-mortalite-et-esperance-de-vie#figures (accessed 24 March 2022)."},{"key":"10.1016\/j.nmd.2023.11.013_bib0025","unstructured":"Cleemput I., Neyt M., Van De Sande S., Thiry N. Belgian guidelines for economic evaluations and budget impact analyses: second edition. vol. 183B 2012."},{"key":"10.1016\/j.nmd.2023.11.013_bib0026","doi-asserted-by":"crossref","unstructured":"Cleemput I., Neyt M., Thiry N., De Laet C., Leys M. Threshold values for cost-effectiveness in health care. 2008.","DOI":"10.57598\/R100C"},{"key":"10.1016\/j.nmd.2023.11.013_bib0027","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7525-1-54","article-title":"The Health Utilities Index (HUI): concepts, measurement properties and applications","volume":"1","author":"Horsman","year":"2003","journal-title":"Heal Qual Life Outcomes"},{"key":"10.1016\/j.nmd.2023.11.013_bib0028","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40273-021-01115-5","article-title":"Systematic literature review to identify utility values in patients with spinal muscular atrophy (SMA) and their caregivers","volume":"40","author":"Sutherland","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.nmd.2023.11.013_bib0029","unstructured":"INAMI. Honoraires, prix et remboursements. 30\/03\/2023 2023. https:\/\/www.riziv.fgov.be\/fr\/themes\/cout-remboursement\/par-mutualite\/prestations-individuelles\/prix\/Pages\/default.aspx (accessed 31 March 2023)."},{"key":"10.1016\/j.nmd.2023.11.013_bib0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/08830738211040292","article-title":"Parent perceptions in choosing treatment for infants with spinal muscular atrophy diagnosed through newborn screening","volume":"37","author":"Deng","year":"2022","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2023.11.013_bib0031","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/dmcn.15286","article-title":"Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening","volume":"65","author":"Dangouloff","year":"2023","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2023.11.013_bib0032","doi-asserted-by":"crossref","first-page":"e1527","DOI":"10.1212\/WNL.0000000000200986","article-title":"Newborn screening for spinal muscular atrophy in New York State: clinical outcomes from the first 3 years","volume":"99","author":"Lee","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.nmd.2023.11.013_bib0033","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","article-title":"Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years","volume":"16","author":"Vill","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2023.11.013_bib0034","doi-asserted-by":"crossref","DOI":"10.3390\/ijns7010015","article-title":"Neonatal screening in Europe revisited: an ISNS perspective on the current state and developments since 2010","volume":"7","author":"Loeber","year":"2021","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.nmd.2023.11.013_bib0035","unstructured":"Haute Autorit\u00e9 de sant\u00e9, LASSERRE Andrea, NAOUR Nadia ZP. Crit\u00e8res d'\u00e9valuation pour l'int\u00e9gration de nouvelles maladies au programme national du d\u00e9pistage \u00e0 la naissance. 16\/03\/2023 2023. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2023-03\/guide_methodologique_depistage_neonatal.pdf (accessed 3 April 2023)."},{"key":"10.1016\/j.nmd.2023.11.013_bib0036","unstructured":"Chris D.L., Germaine H., Erik H. D\u00e9pistage n\u00e9onatal sanguin\u00a0: analyse de d\u00e9cision multicrit\u00e8re pour s\u00e9lectionner les maladies prioritaires. Bruxelles: centre F\u00e9d\u00e9ral d'Expertise des Soins de Sant\u00e9 (KCE); 2016. 10.57598\/R267BS."},{"key":"10.1016\/j.nmd.2023.11.013_bib0037","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jval.2012.02.007","article-title":"Cost-effectiveness of expanded newborn screening in Texas","volume":"15","author":"Tiwana","year":"2012","journal-title":"Value Heal J Int Soc Pharmacoeconom Outcomes Res"},{"key":"10.1016\/j.nmd.2023.11.013_bib0038","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ymgme.2011.07.007","article-title":"A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID)","volume":"104","author":"Chan","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2023.11.013_bib0039","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00431-019-03346-3","article-title":"Cost-effectiveness of newborn screening for severe combined immunodeficiency","volume":"178","author":"Van der Ploeg","year":"2019","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.nmd.2023.11.013_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijns8030044","article-title":"Economic evaluation of newborn screening for severe combined immunodeficiency","volume":"8","author":"Shih","year":"2022","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.nmd.2023.11.013_bib0041","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(22)00125-9","article-title":"Emerging therapies for Duchenne muscular dystrophy","volume":"21","author":"Markati","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.11.013_bib0042","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/13543784.2021.1939674","article-title":"Therapies in preclinical and clinical development for Angelman syndrome","volume":"30","author":"Markati","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.nmd.2023.11.013_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.695937","article-title":"Current and future prospects for gene therapy for rare genetic diseases affecting the brain and spinal cord","volume":"14","author":"Jensen","year":"2021","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.nmd.2023.11.013_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc"},{"key":"10.1016\/j.nmd.2023.11.013_bib0045","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/genes14071377","article-title":"Spinal muscular atrophy treatment in patients identified by newborn screening \u2013 a systematic review","volume":"14","author":"Aragon-Gawinska","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.nmd.2023.11.013_bib0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230677","article-title":"Diagnostic journey in spinal muscular atrophy: is it still an odyssey?","volume":"15","author":"Pera","year":"2020","journal-title":"PLoS ONE"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623008106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623008106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:14:37Z","timestamp":1760775277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896623008106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":46,"alternative-id":["S0960896623008106"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2023.11.013","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2023.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}